T. Rowe Price CEO Robert Sharps joins Longeviti Neuro Solutions board

Longeviti Neuro Solutions appointed Robert W. Sharps, chief executive officer and president of T. Rowe Price Group Inc. (NASDAQ: TROW), to its board of directors, the Baltimore-based neurotechnology company announced.

Sharps brings three decades of experience in global asset management, capital markets, corporate governance and strategic growth to the role. As CEO and chairman of T. Rowe Price, he oversees the investment firm managing more than $1.5 trillion in assets for individuals, institutions and retirement investors worldwide.

"Rob's leadership and perspective at the intersection of finance, governance, and long-term value creation will be invaluable as Longeviti continues to grow," said Jesse Christopher, founder of Longeviti Neuro Solutions. "His experience guiding a global investment organization will help strengthen our strategic planning, governance, and partnerships as we scale the company."

Longeviti develops implantable and AI-enabled solutions for neurological health, including its ClearFit AI platform, which the company describes as the first Acoustic Brain Interface. The platform integrates advanced imaging, artificial intelligence and precision engineering to enhance planning, placement and analysis for neurotechnology and implantable solutions.

"I am pleased to join the board of Longeviti Neuro Solutions during a period of significant advancement in neuroscience and medical technology," Sharps said. "The company's work combining artificial intelligence, data insights, and innovative neurotechnology represents an important opportunity to improve the way neurological conditions are studied and treated."

Sharps joined T. Rowe Price in 1997 and became CEO and president in 2022. He previously served as chief investment officer and head of investments, overseeing the firm's global investment platform.

Longeviti holds more than 50 patents worldwide and has products approved for use in over 120 hospitals globally. The company reports its neurosurgical implants have been used in more than 4,000 patients to date.

You May Also Be Interested In

• Transcat names Roy Simmons as chief strategy officer
• John Rogers Jr. to leave Nike board after eight years of service
• Spruce Biosciences names medical affairs VP ahead of drug review